EIKN Eikon Therapeutics, Inc.

CIK 0001861123 8 ready 8-Ks latest August 13, 2026, 8:44 PM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline

Ready 8-Ks 8

Latest filing August 13, 2026, 8:44 PM ET

Top materiality 0.80

Event mix earnings ×3 · leadership ×2 · other_material ×2

Sentiment 1 pos · 0 neg · 7 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for EIKN

Highest-materiality recent filing

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

June 1, 2026, 7:30 AM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).
Non-squamous cohort: ORR 55.6%, DCR 83.3%, median DOR >11 months at 13.6 months follow-up.

Read filing →

August 13, 2026, 8:44 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Eikon Therapeutics updates Q3 2026 corporate presentation; details not disclosed in filing

Eikon Therapeutics (EIKN) furnished an updated Q3 2026 corporate presentation on August 13, 2026.
August 13, 2026, 4:06 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Eikon Q2 2026 net loss $88.4M, cash $531.2M; EIK1001 DMC selects dose

Net loss $88.4M vs $105.2M prior year; R&D $75.5M (+9%), G&A $17.9M (-56%).
August 3, 2026, 4:39 PM ET leadership materiality 0.40 neutral item 5.02

Two directors resign from Eikon Therapeutics board effective July 31, 2026

Leon Chen, Ph.D. resigned from the Board of Directors.
June 10, 2026, 4:15 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

Eikon Therapeutics appoints Ma. Fatima D. Francisco to Board as Class I director

Appointment effective June 15, 2026; serves until 2027 annual meeting.
June 1, 2026, 7:30 AM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).
May 11, 2026, 4:05 PM ET earnings materiality 0.80 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance

Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.
March 30, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Eikon Therapeutics reports Q4/FY2025 net loss $79.7M/$333.6M; IPO raised $381M

Net loss attributable to common stockholders was $79.7M in Q4 2025 and $333.6M for full year 2025.
February 6, 2026, 6:59 PM ET other material materiality 0.40 neutral item 5.03 item 9.01 ◈ Governance Changes ×2

Eikon adopts amended charter and bylaws upon IPO closing on Feb 6, 2026

IPO of common stock closed on February 6, 2026 per the company's S-1 registration.

Executive changes

Appointed

Ma. Fatima D. Francisco

Class I director

EIKN · Eikon Therapeutics, Inc.

Effective: 2026-06-15
Filed: June 10, 2026, 4:15 PM ET

the Board of Directors (the “Board”) of Eikon Therapeutics, Inc. (the “Company”) appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026.

Earnings & guidance

2026-Q1 EPS reported -$2.46 filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.50 · Most common event earnings

1 positive 0 negative 7 neutral

source · EIKN on sec.gov